STORM Therapeutics’ collaborator awarded ASH–BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition
09 December 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics announces today, that its collaborator Dr. Konstantinos Tzelepis, Sir Henry Wellcome Fellow and Visiting Scientist at the Wellcome Sanger Institute, received the ASH-BSH Abstract Achievement Award for his work on STORM Therapeutics’ lead programme, METTL3, at the 61st Annual Meeting of the American Society of Hematology (ASH) held on 7th-10th December 2019 in Orlando, Florida.
Dr. Tzelepis received the meritorious award for his abstract entitled ‘Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutics Strategy for Acute Myeloid Leukemia’ at the Abstract Achievement Award Ceremony which was held on Saturday, 7th December 2019 at 3:30pm (EST) at the Orange County Convention Center in Exhibit Hall B2-B4.
